$285.75
0.79%
NYSE, Nov 13, 04:21 pm EST. Closed.
ISIN
US4781601046
Symbol
JNJ

Johnson & Johnson Stock price

$285.75
+37.14 14.94% 1M
+55.33 24.01% 6M
+78.80 38.08% YTD
+90.50 46.35% 1Y
+138.12 93.56% 3Y
+122.23 74.75% 5Y
+169.15 145.07% 10Y
+219.81 333.35% 20Y
NYSE, Closing price Fri, Nov 13 2026
+2.23 0.79%

AI Insights on Johnson & Johnson Insights AI Insights on Johnson & Johnson

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?
How is the company managed?

Create a Free Account to create an Johnson & Johnson alert.

Set up alerts on Stock Price, Dividend Yield, Valuation (e.g. P/E or EV/Sales) or Strategy Scores and sit back and relax.

Key metrics

Basic
Market capitalization
$687.9b
Enterprise Value
$715.3b
Net debt
$27.4b
Cash
$17.2b
Shares outstanding
2.4b
Valuation
P/E
43.4
P/S | estimate
6.9 | 6.7
EV/Sales | estimate
7.2 | 7.0
EV/FCF | ex SBC
34.7 | 37.3
P/B
8.4
Dividends
DPS
$5.32
Yield 1Y | 5Y
1.9% | 2.7%
Growth 1Y | 5Y
3.5% | 4.9%
Payout 1Y | 3Y
46.6% | 48.3%
Increased
25 Years
Financials
Revenue | estimate
$99.3b | $102.2b
EBITDA
$34.5b
EBIT
$26.4b
Net Income
$16.1b
Free Cash Flow | ex SBC
$20.6b | $19.2b
Growth
Revenue | estimate
7.8% | 8.5%
EBITDA
7.0%
EBIT
6.2%
Net Income
-35.9%
Free Cash Flow
5.1%
Margin
Gross
67.7%
EBITDA
34.7%
EBIT
26.6%
Net
16.2%
Free Cash Flow | ex SBC
20.7% | 19.3%
Financial Health
Equity Ratio
40.9%
Return on Equity
32.9%
ROCE
18.6%
ROIC
14.2%
Debt/Equity
0.5
Share-Based Compensation & Dilution
SBC | % of Revenue
$1.4b | 1.4%
SBC as % of FCF
6.9%
SBC Growth 1Y
11.0%
Share Count Growth 1Y
0.0%
Shareholder Yield
1.8%
More
EPS
$6.6
FCF per Share
$8.6
Short interest
0.8%
Employees
138k
Rev per Employee
$680.0k

Johnson & Johnson Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Johnson & Johnson forecast:

21x Buy
70%
9x Hold
30%

Analyst Opinions

30 Analysts have issued a Johnson & Johnson forecast:

Buy
70%
Hold
30%

Johnson & Johnson Events

Past Events
OCT
13
Q3 2026 Earnings Call
about one month ago
SEP
17
Deutsche Bank 2026 Healthcare Summit
about 2 months ago
SEP
14
Morgan Stanley 24th Annual Global Healthcare Conference
2 months ago
SEP
9
Wells Fargo 21st Annual Healthcare Conference
2 months ago
AUG
3
Special Call - Johnson & Johnson
3 months ago
JUL
15
Q2 2026 Earnings Call
4 months ago
JUN
9
Goldman Sachs 47th Annual Global Healthcare Conference 2026
5 months ago
MAY
27
Bernstein 42nd Annual Strategic Decisions Conference
6 months ago
MAY
19
RBC Capital Markets Global Healthcare Conference 2026
6 months ago
MAY
12
Bank of America Global Healthcare Conference 2026
6 months ago
APR
14
Q1 2026 Earnings Call
7 months ago
MAR
10
Barclays 28th Annual Global Healthcare Conference
8 months ago
MAR
3
TD Cowen 46th Annual Health Care Conference
9 months ago
JAN
21
Q4 2025 Earnings Call
10 months ago
JAN
12
44th Annual J.P. Morgan Healthcare Conference
10 months ago
DEC
3
Citi Annual Global Healthcare Conference 2025
12 months ago
NOV
17
7th Annual Wolfe Research Healthcare Conference
12 months ago
NOV
11
UBS Global Healthcare Conference 2025
about one year ago
NOV
11
Guggenheim Securities 2nd Annual Healthcare Innovation Conference
about one year ago

Financial data from Johnson & Johnson

Sep '26
+/-
%
99,335 99,335
8% 8%
100%
- Direct Costs 32,098 32,098
9% 9%
32%
67,237 67,237
7% 7%
68%
- Selling and Administrative Expenses 25,466 25,466
9% 9%
26%
- Research and Development Expense 16,079 16,079
2% 2%
16%
34,509 34,509
7% 7%
35%
- Depreciation and Amortization 8,091 8,091
10% 10%
8%
EBIT (Operating Income) EBIT 26,418 26,418
6% 6%
27%
Net Profit 16,095 16,095
36% 36%
16%

In millions USD.

Don't miss a Thing! We will send you all news about Johnson & Johnson directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Johnson & Johnson Stock News

Neutral
Business Wire
●
5 days ago
DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a verdict in the amount of $1,914,990 accompanied by court ordered interest of $1,410,541 for a sum total of $3,325,631 against Johnson & Johnson on behalf of the family of Winifred “Missy” Haddad, a Massachusetts woman who developed mesothelioma after years of using the company's talcum-b...
Positive
Reuters
●
6 days ago
Johnson & Johnson said on Tuesday its drug Caplyta eased manic symptoms better than placebo in a second late-stage ​study of patients with bipolar I disorder, paving the ‌way for a planned US regulatory filing.
Neutral
Business Wire
●
6 days ago
DALLAS--(BUSINESS WIRE)--National plaintiffs trial firm Dean Omar Branham Shirley, LLP, (DOBS) has secured a $3,325,000 jury verdict against Johnson & Johnson on behalf of the family of Winifred “Missy” Haddad, a Massachusetts woman who developed mesothelioma after years of using the company's talcum-based baby powder. Jurors in Suffolk County Superior Court found that Johnson & Johnson's baby ...
More Johnson & Johnson News

Company Profile

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Head office United States
CEO Mr. Duato
Employees 138,200
Founded 1887
Website www.jnj.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today